Showing 21 of 54 results

PATH, Agence de Médecine Préventive (AMP), World Health Organization
The MenAfriVac CTC experience in Benin: English version
Organisation Mondiale de la Santé (OMS), Agence de Médecine Préventive (AMP), PATH
Reportage sur l'utilisation du MenAfrivac en CTC
World Health Organization
The meningitis road map has been designated as a flagship global strategy of the WHO’s Thirteenth General Programme of Work, 2019–2023 and is an essential component in achieving universal health...
Organisation Mondiale de la Santé (OMS)
La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du...
Mark R. Alderson, Jo Anne Welsch, Katie Regan, Lauren Newhouse, Niranjan Bhat, Anthony A. Marfin
Despite advances in the development and introduction of vaccines against the major bacterial causes of meningitis, the disease and its long-term after-effects remain a problem globally. The Global...
World Health Organization
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...
World Health Organization
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines...
World Health Organization
Until recently, most meningitis epidemics in the meningitis belt of sub-Saharan Africa were due to Neisseria meningitidis serogroup A (NmA), such that the existing WHO guidelines have been directed...
World Health Organization
This document aims to provide standardized guidance for public health authorities and investigators at all levels to plan and conduct the investigation of every meningitis case of Nm A. This...
World Health Organization
Since 2010, the Neisseria meningitidis (Nm) A conjugate vaccine is being introduced on a large scale in countries of the African meningitis belt. It is expected that this vaccination programme will...
Telisinghe L, Waite TD, Gobin M, Ronveaux O, Fernandez K, Stuart JM, Scholten RJ.
Household contacts of an index case of invasive meningococcal disease (IMD) are at increased risk of acquiring disease. In revising WHO guidance on IMD in sub-Saharan Africa, a systematic review was...
Mvundura et all
An economic evaluation of the controlled temperature chain approach for vaccine logistics: evidence from a study conducted during a meningitis A vaccine campaign in Togo
World Health Organization
Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à températtrôlée (CTC) pendant les campagnes - Guide d\'adaptation et guide du formateur
World Health Organization
Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à température contrôlée (CTC) pendant les campagnes - Module de formation pour l\'organisation de séances de vaccination
De Oliveira et al.
To summarize and critically evaluate the evidence on the impact and effectiveness of meningococcal vaccination programs around the world in order to inform decision-making in Latin America and the...
Natalya Nepomnyashch
As of May 2017, two medical laboratory scientists employed by the Sokoto State Government, jointly trained by the University of Nebraska Medical Centre and eHA are operating the lab. During the 2017...
PATH
This fact sheet describes PATH’s efforts to eliminate meningococcal meningitis epidemics from Africa, once and for all. It covers work across meningitis projects, including the development and...
Caroline L Trotter et al.
Background: In preparation for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance network was...
Sidikou F, Zaneidou M, Alkassoum I, Schwartz S, Issaka B, Obama R, Lingani C, Tate A, Ake F, Sakande S, Ousmane S, Zanguina J, Seidou I, Nzeyimana I, Mounkoro D, Abodji O, Wang X, Taha MK, Moulia-Pelat JP, Pana A, Kadade G, Ronveaux O, Novak R, Oukem-Boyer OO, Meyer S, MenAfriNet consortium
BACKGROUND: To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressively rolled...
Ana L. Andrade, Ruth Minamisava, Lisia M. Tomich, Ana P. Lemos, Maria C. Gorla, Maria C. de Cunto Brandileone, Carla Magda S Domingues, Camile de Moraes, Gabriela Policena, Ana L. Bierrenbach
BACKGROUND: Routine infant immunization with meningococcal C conjugate (MCC) vaccination started in Brazil in November 2010, scheduled at three and five months plus a booster at 12-15months of age....